Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway

• Egile Nagusiak: Teng Chen (Egilea), Pei Zhang (Egilea), Xiao-Fan Cong (Egilea), Yuan-Yuan Wang (Egilea), Shuo Li (Egilea), Hao Wang (Egilea), Su-Rong Zhao (Egilea), Xiao-Jin Sun (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

IntroductionAlmonertinib is an important third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) exhibiting high selectivity to EGFR-sensitizing and T790M-resistant mutations. Almonertinib resistance is a major obstacle in clinical use. Baicalein possesses antitumor pr...